For patients with primary biliary cholangitis, more receiving the peroxisome proliferator-activated receptor delta (PPARδ) agonist seladelpar have a biochemical response and alkaline phosphatase normalization, according to a study published online Feb. 21 in the New England Journal of Medicine. Gideon M. Hirschfield, Ph.D., from the University Health Network in Toronto, and colleagues conducted a phase...